In recent trading session, Royalty Pharma plc (NASDAQ:RPRX) saw 3,588,496 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $42.98 trading at $0.5 or 1.18% at recent trade assigns it a market valuation of $25.48 Billion. That current trading price of RPRX’s stock is at a discount of -31.46% from its 52-week high price of $56.5 and is indicating a premium of 10.33% from its 52-week low price of $38.54. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1Million shares which gives us an average trading volume of 1.02 Million if we extend that period to 3-months.
For Royalty Pharma plc (RPRX), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.6. Splitting up the data highlights that, out of 6 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0.59 in the current quarter.
Royalty Pharma plc (NASDAQ:RPRX) trade information
Wall Street analysts have assigned a consensus price target of $51.8 to the stock, which implies a rise of 20.52% to its current value. Analysts have been projecting $47 as a low price target for the stock while placing it at a high target of $56. It follows that stock’s current price would jump +30.29% in reaching the projected high whereas dropping to the targeted low would mean a loss of 9.35% for stock’s current value.
Royalty Pharma plc (RPRX) estimates and forecasts
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $453.57 Million for the same. And 4 analysts are in estimates of company making revenue of $459.4 Million in the next quarter that will end in December 01, 2020.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 70.5% while estimates for its earnings growth in next 5 years are of 6.8%
Royalty Pharma plc is more likely to be releasing its next quarterly report between August 12 and August 12, 2020, and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 1.4%, the share has a forward dividend of 0.6 which implies that company’s dividend yield remained growing in trailing twelve months.
Royalty Pharma plc (NASDAQ:RPRX)’s Major holders
The second largest institutional holder is FMR, LLC, which was holding about 16.36 Million shares on June 29, 2020. The number of shares represents firm’s hold over 4.47% of outstanding shares, having a total worth of $794.11 Million.
On the other hand, Investment Company Of America and Vanguard Specialized-Health Care Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 3659399 shares of worth $177.66 Million or 1% of the total outstanding shares. The later fund manager was in possession of 3.05 Million shares on July 30, 2020, making its stake of worth around $131.45 Million in the company or a holder of 0.83% of company’s stock.